@article{10902/32069,
year = {2020},
url = {https://hdl.handle.net/10902/32069},
abstract = {In the last 2 decades, several neuroimaging studies investigated brain abnormalities associated with the early stages of psychosis in the hope that these could aid the prediction of onset and clinical outcome. Despite advancements in the field, neuroimaging has yet to deliver. This is in part explained by the use of univariate analytical techniques, small samples and lack of statistical power, lack of external validation of potential biomarkers, and lack of integration of nonimaging measures (eg, genetic, clinical, cognitive data). PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis which uses machine learning techniques to analyze imaging, clinical, cognitive, and biological data with the aim of facilitating the prediction of psychosis onset and outcome. In this article, we provide an overview of the PSYSCAN protocol and we discuss benefits and methodological challenges of large multicenter studies that employ neuroimaging measures.},
organization = {The PSYSCAN Project is supported by grant agreement no. 603196 under the European Union’s Seventh
Framework Programme.
We would like to thank all participants who took part in the study. Conflict of Interest: S.G. received honoraria,
advisory board, or consulting fees from the following companies: Gedeon-Richter, Janssen Pharmaceuticals,
Janssen-Cilag Polska Sp. z o.o, Otsuka, Pierre Fabre and Sunovion Pharmarmaceuticals. B.G. is the leader of a
Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia
Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on
international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the
University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck
A/S for another independent investigator initiated study. All grants are the property of the Mental Health Services
in the Capital Region of Denmark and administrated by them. G.S. is president of the Austrian Society of
Neuropsychopharmacology and Biological Psychiatry, which is partially financed by the support from pharmaceutical companies. G.S. received consulting fees and/or honoraria for speeches within the last 3 years from Angelini, AOP Orphan, Alkermes, Janssen, Lundbeck, Pfizer. PFP received advisory board fees and research
funds from Lundbeck.},
publisher = {Oxford University Press},
publisher = {Schizophrenia Bulletin, 2020, 46(2), 432-441},
title = {Towards precision medicine in psychosis: Benefits and challenges of multimodal multicenter studies - PSYSCAN: translating neuroimaging findings from research into clinical practice},
author = {Tognin, Stefania and Hell, Hendrika H. van and Merritt, Kate and Winter-van Rossum, Inge and Bossong, Matthijs G. and Kempton, Matthew J. and Modinos, Gemma and Fusar-Poli, Paolo and Mechelli, Andrea and Dazzan, Paola and Maat, Arija and De Haan, Lieuwe and Crespo Facorro, Benedicto and Glenthoj, Birte and Lawrie, Stephen M. and McDonald, Colm and Gruber, Oliver and Amelsvoort, Therese van and Arango, Celso and Kircher, Tilo},
}